Compare EOG Resources Inc (EOG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Novo Nordisk A/S — how do they compare? EOG Resources Inc trades at $144 (market cap $75.22B), while Novo Nordisk A/S trades at $46.49 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 2.8× EOG Resources Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EOG | NVO | |
|---|---|---|
Market Cap | $75.22B | $207.85B |
Sector | Energy | Health |
52-Week High | $149.89 | $63.98 |
52-Week Low | $101.78 | $35.29 |
Enterprise Value | $78.56B | $222.55B |
Dividend Yield | 2.85% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $142.93, up 0.5% today, with a bullish technical outlook and strong fundamentals. The stock exhibits robust profitability with a 25.81% net income margin and 22.51% ROE, supported by three consecutive quarterly earnings beats. Analysts are overwhelmingly positive with a $157.88 consensus target and no sell ratings. Recent news highlights record Q2 2026 earnings, cost discipline, and promising international exploration.
The outlook for EOG is favorable, driven by strong cash flow generation, shareholder returns, and operational efficiency. Key risks include oil price volatility and capital expenditure intensity. With solid institutional support and a discounted valuation, the stock presents a compelling opportunity for growth-oriented investors seeking energy exposure.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
